COMP <GO>
DXCM vs WST // OPERATING MARGIN
DexCom Inc. (NASDAQ) VS. West Pharmaceutical Services Inc. (NYSE) • 15-METRIC TALLY: DXCM 10
— WST 3
▲ OPERATING MARGIN LEADER: DXCM
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
operating-margins
19.60%
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
operating-margins
19.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. WST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | WST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 35.90% | +24.20 | DXCM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 17.90% | +3.70 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 34.7x | -9.50 | DXCM | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 1.60% | +1.97 | DXCM | /fcf-yield <GO> |
| Operating Margin ACTIVE | 19.60% | 19.00% | +0.60 | DXCM | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 16.10% | +1.80 | DXCM | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 6.30% | +9.30 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.21% | -0.21 | WST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 19.06 | -11.92 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 77.0 | -35.20 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 55.2x | -24.90 | DXCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $29.32B | $839.0M | DXCM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | WST REV | DXCM GROSS % | WST GROSS % | DXCM FCF | WST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $3.07B | 60.1% | 35.9% | $1.08B | $468.9M |
| FY 2024 | $4.03B | $2.89B | 60.5% | 34.5% | $630.7M | $276.4M |
| FY 2023 | $3.62B | $2.95B | — | — | $585.5M | $643.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
WST // BETA 1.08